MedTrace Logo

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

NCT00524810 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2011-06-30

No results posted yet for this study

Summary

Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

Conditions

Interventions

DRUG

Pegylated liposomal doxorubicin

Caelyx 30 mg/m² day 1 every 3 weeks

DRUG

Docetaxel

Taxotere 75 mg/m² day 2 every 3 weeks

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Laure CHAUVENET, MD, PHD · Hôpital HOTEL DIEU - Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524810 on ClinicalTrials.gov